J&J, Flush With Cash, Has Flexibility To Be ‘Bolder’ On M&A, CEO Duato Says
The company kicked off the new year with a new CEO, plans to break out consumer health, and a strong financial position, including $32bn in cash and lowest level of net debt in more than four years.
You may also be interested in...
Johnson & Johnson reported disappointing Q1 sales for its COVID-19 vaccine but called the Carvykti launch solid and discussed plans for further diversification of its multiple myeloma portfolio.
Mersana will help J&J develop antibody-drug conjugates against three targets, while AstraZeneca out-licenses a candidate for peripheral artery disease to Regio.
In this week's podcast edition of Five Must-Know Things: J&J considers bold M&A moves; a prominent new CEO for Galapagos; Biogen’s interim leader talks to Scrip; a view on Biogen and M&A; and a look at Astellas’ digital shift plans.